<html xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>   <meta charset="utf-8" />
<meta http-equiv=Content-Type content="text/html; charset=Windows-1254">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<link rel=File-List href="inmetedavi_dosyalar/filelist.xml">
<title>�SKEM�K BEY�N DAMAR HASTALIKLARINDA TANI VE TEDAV� YAKLA�IMLARI</title>
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:1627421319 -2147483648 8 0 66047 0;}
@font-face
	{font-family:Calibri;
	mso-font-alt:"Times New Roman";
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
h1
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:16.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h2
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:14.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h3
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:13.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h4
	{margin:0cm;
	margin-bottom:.0001pt;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:bold;
	font-style:italic;}
h5
	{margin:0cm;
	margin-bottom:.0001pt;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:5;
	font-size:12.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
h6
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:150%;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:6;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman";
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	mso-outline-level:7;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	mso-outline-level:8;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:36.0pt;
	line-height:150%;
	mso-pagination:widow-orphan;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:150%;
	mso-pagination:widow-orphan;
	layout-grid-mode:char;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.abstract, li.abstract, div.abstract
	{mso-style-name:abstract;
	mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
span.char
	{mso-style-name:char;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
span.char0
	{mso-style-name:char0;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
span.char1
	{mso-style-name:char1;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
span.char2
	{mso-style-name:char2;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;
	font-style:italic;}
span.char3
	{mso-style-name:char3;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
span.char4
	{mso-style-name:char4;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
span.char5
	{mso-style-name:char5;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.char6
	{mso-style-name:char6;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.char7
	{mso-style-name:char7;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.char8
	{mso-style-name:char8;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.char9
	{mso-style-name:char9;
	font-family:Tahoma;
	mso-ascii-font-family:Tahoma;
	mso-hansi-font-family:Tahoma;
	mso-bidi-font-family:Tahoma;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 @list l0
	{mso-list-id:531460496;
	mso-list-template-ids:-186979190;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1
	{mso-list-id:2097626682;
	mso-list-template-ids:123360588;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Normal Tablo";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
</style>
<![endif]-->
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:36.0pt'>

<div class=Section1>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;punctuation-wrap:simple;
text-autospace:none'><b><span lang=TR style='font-size:16.0pt;line-height:150%;
font-family:Tahoma;mso-ansi-language:TR'>�SKEM�K BEY�N DAMAR HASTALIKLARINDA
TANI VE TEDAV� YAKLA�IMLARI</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><b><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><b><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Yakup KRESP�, Sara ZARKO BAHAR</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Son g�ncelle�tirme tarihi: <b>31.05.2009</b></span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

</div>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:normal;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�nme �nemli halk sa�l���
sorunlar�ndan biridir. Geli�mi� toplumlarda ���nc� �l�m nedeni ve birinci
sakatl�k sebebidir. �nme yaln�z hastay� de�il t�m hasta ailesini olumsuz
etkileyen bir durumdur. �nmenin yol a�t��� sakatl�k geli�mi� toplumlarda sa�l�k
ekonomisi �zerine b�y�k bir y�k olu�turur. T�m bu olumsuz sonu�lar�na ra�men
inme geli�mi� �lkelerde dahi �ok yak�n bir ge�mi�e dek halk sa�l��� programlar�
i�inde koroner damar hastal�klar�n�n g�lgesinde kalm��t�r. Bunun en �nemli
nedenlerinden biri hi� ��phesiz tedavisi m�mk�n olmayan bir hastal�k gibi g�r�lm��
olmas�d�r. �nme veya di�er dillerdeki kar��l��� olan �stroke� kelimesi her ne
kadar hastal���n aniden ortaya ��kan bir durum oldu�unu tan�mlasa bile, bu
hastal���n sonu�lar� kar��s�nda hekimin kar�� kar��ya kald��� �aresizli�e ve
umutsuzlu�a da bir anlamda vurgu yapmaktad�r. Halk inme risk fakt�rlerini ve
inme semptomlar�n� pek iyi bilmemektedir. Hastalar semptomlar�n�n fark�na varsa
bile miyokard infarkt�s�n�n aksine bir sa�l�k kurumuna ba�vurmak yerine
semptomlar�n kendili�inden ge�mesini beklemekte, �o�unlukla acil bir birime
gecikerek ula�makta ve g�ncel tedavi yakla��mlar�ndan pek yararlanamamaktad�r.
Bunlardan daha da �nemlisi sa�l�k �al��anlar� hangi kademede olursa olsun
inmeli hastaya yakla��m konusunda iyi e�itimli de�ildir ve bu hastal��� halen
�aresi olmayan bir durum olarak alg�lamaktad�r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Son y�llarda inmeden koruyucu
y�ntemlerin yan�s�ra, inme tekrar�n�n �nlenmesi ve �zellikle inmeli hastalar�n
akut d�nemde tan�, tedavi ve bak�mlar� a��s�ndan �nemli ilerlemeler
kaydedilmi�tir. Kitab�n �Beyin Kanamas�� ve �Serebral Ven�z Tromboz�
b�l�mlerinde hemorajik inme ve serebral ven trombozlar�n tan� ve tedavileri
ayr�nt�l� bir �ekilde i�lendi�inden bu b�l�mde arteryel t�kanma sonucu ortaya
��kan iskemik inme tan� ve tedavisinde kaydedilen ilerlemeler �zetlenmeye
�al���lacakt�r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><b><span
lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><b><span
lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>TANI</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><b><span lang=TR style='font-size:13.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>�skemik inme ��phesi
olan hastalarda ilk tan�sal de�erlendirmenin ama�lar� nelerdir?</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�skemik inme acil bir medikal
durumdur. Hastan�n acile ba�vurdu�unda yap�lan tan�sal de�erlendirmeden elde
edilecek bulgular hem hastan�n prognozunu belirlemede hem de do�ru tedavilerin
ba�lat�lmas�nda �nemlidir. Acilde yap�lan ilk de�erlendirmenin ama�lar� t�m
inme tipleri i�in ayn�d�r ve ��ylece �zetlenebilir:</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='line-height:normal;mso-list:l0 level1 lfo1;
     tab-stops:list 36.0pt'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Hastan�n n�rolojik �ikayetlerinin inme nedeniyle ortaya ��kt���na
     karar vermek, inmeyi taklit edebilecek medikal ve di�er n�rolojik
     hastal�klar� d��lamak </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l0 level1 lfo1;
     tab-stops:list 36.0pt'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Beyin<span style='color:red'> </span>hasar�n�n geli�ti�i b�lgeyi
     lokalize etmek </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l0 level1 lfo1;
     tab-stops:list 36.0pt'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>Hemorajik ve iskemik inme aras�nda ay�r�c� tan�y� yapmak </span><span
     lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l0 level1 lfo1;
     tab-stops:list 36.0pt'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>�nmeye yol a�an nedene y�nelik ilk bilgileri toplamak </span><span
     lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l0 level1 lfo1;
     tab-stops:list 36.0pt'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
     TR'>�nme seyrinde ortaya ��kabilecek akut n�rolojik ve medikal
     komplikasyonlar� ortaya koymak </span><span lang=TR style='mso-ansi-language:
     TR'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
normal;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-size:13.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><b><span lang=TR style='font-size:13.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>�skemik inme ��phesi
olan hastalarda nas�l tan� konur? </span></b><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>(<b>Tablo 1</b>)</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;line-height:150%;
page-break-after:avoid;text-autospace:none'><b><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;line-height:150%;
page-break-after:avoid;text-autospace:none'><span lang=TR style='font-family:
Tahoma;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/svh/inmetedavi1.htm"><b><span
style='font-size:10.0pt;line-height:150%'>Tablo 1.</span></b></a></span><b><u><span
lang=TR style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'> </span></u></b><span lang=TR style='font-size:10.0pt;line-height:150%;
font-family:Tahoma;mso-ansi-language:TR'>Acilde inmeli hastaya yakla��m
algoritmas�</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Klinik karar: �nme mi?</span></i></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Hastan�n n�rolojik
�ikayetlerinin inme nedeniyle ortaya ��kt���n�n ve hasar�n s�rmekte oldu�u
beyin b�lgesinin belirlenmesi do�ru bir klinik de�erlendirme sonucunda ortaya
konulabilir (bak�n�z: <a href="http://www.itfnoroloji.org/svh/bdhtanimlar.htm">Tan�mlar,
S�n�flama, Epidemiyoloji ve Risk Fakt�rleri</a> ve <a
href="http://www.itfnoroloji.org/svh/vaskulersend.html">N�rovask�ler Sendromlar</a>
). Bu de�erlendirme ilk bak��ta bir �ok hekime zor ve karma��k gibi g�r�nse de
bu yanl�� bir �nyarg�d�r. D�nya Sa�l�k �rg�t�'ne g�re inme; vask�ler neden
d���nda g�r�n�rde ba�ka bir neden olmadan, aniden yerle�ip, fokal&nbsp; (veya
global) serebral disfonksiyona yol a�an, 24 saat veya daha uzun s�rebildi�i gibi
�l�mle de sonu�lanabilen klinik bir durumdur. Bu tan�m beyin kanamas�,
subaraknoid kanama, arteryel veya ven�z t�kanmalar sonucu ortaya ��kan beyin
infarkt�na ba�l�, �e�itli tipte beyin damar hastal�klar� sonucu geli�en klinik
durumlar� yans�t�r. Bu tan�m�n ve hastalar� acile getiren en s�k beyin
disfonksiyonu �ikayetlerinin neler oldu�unun ak�lda tutulmas� (bak�n�z: <a
href="http://www.itfnoroloji.org/svh/bdhtanimlar.htm">Tan�mlar, S�n�flama,
Epidemiyoloji ve Risk Fakt�rleri</a>) hastalar�n �o�unda inme �n tan�s�n�n
konulmas�n� sa�lar. Bu de�erlendirmede en �nemli basamak olan hastal�k
anamnezini al�rken sorgulanmas� gereken en �nemli durum hastan�n �ikayetlerinin
aniden ortaya ��km�� olup olmad���d�r. Aniden ortaya ��kan �ikayetler daha
sonra �e�itli tipte (dalgalanma, progresif k�t�le�me, hecmelerle k�t�le�me)
seyir g�sterebilir. <i>Anamnezde inme semptomlar�n�n ba�lang�c�ndan beri ge�en
s�re de sorgulanmal�d�r. S�renin belirlenmesi daha sonra de�inilecek olan
tedavi indikasyonlar�n�n belirlenmesinde �ok �nemlidir. Bu ama�la hastan�n son
olarak sa�lam g�r�ld��� saatten yak�nmalar�n�n kaybolmas�na veya ilk g�r�lene
dek ge�en s�re hesaplan�r. �ikayetler hasta uykudan uyand���nda fark edilmi�se,
s�re son olarak sa�lam g�r�ld��� saatten yak�nmalar�n�n kaybolmas�na veya ilk
g�r�lene dek ge�en s�redir.</i></span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Lokalizasyon: Beynin hangi b�lgesi hasarlanm��?</span></i></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Beyin disfonksiyonunu
yans�tan �ikayetler (bak�n�z: <a
href="http://www.itfnoroloji.org/svh/bdhtanimlar.htm">Tan�mlar, S�n�flama,
Epidemiyoloji ve Risk Fakt�rleri</a>) i�inde v�cudun bir yar�s�nda ortaya ��kan
uyu�ukluk ve g��s�zl�k ile konu�ma ve anlama bozuklu�unun �n planda serebral
hemisferlere ait bir bulgu oldu�u, ba� d�nmesi dengesizlik ve �ift g�rmenin
beyin sap� tutulumunu yans�tt���, ani ve tek ba��na ortaya ��kan ciddi bir ba�
a�r�s�n�n da ba�l�ca subaraknoid mesafeye kanama nedeniyle ortaya ��kt��� her
hekimin bilgi da�arc���nda yer almas� gereken, h�zl� ve kaba lokalizasyonun
yap�labilmesini sa�layan bilgilerdir. H�zl� bir n�rolojik muayenede uyan�kl�k
durumu, nistagmus ve di�er ok�lomotor defisitlerin, motor ve duysal defisitin,
hemianopsi, afazi, trunkal ve appendik�ler ataksi gibi bulgular�n varl���
ortaya konularak daha iyi bir lokalizasyon yap�labilir. Bulant� ve kusma
intrakranyal bas�nc�n artm�� oldu�unu, meningeal irritasyon bulgular� da
subaraknoid mesafenin tutuldu�unu g�steren bulgulard�r. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>G�r�nt�leme; Hemorajik inme mi? �skemik inme mi?</span></i></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Anamnez ve n�rolojik
muayene a�amas�ndan sonra en �nemli basamak klinik �n tan�y� do�rulamak ve
hemorajik inme ile iskemik inme aras�nda ay�r�c� tan�y� yapmakt�r. Bu ay�r�m
uygulanacak tedavi stratejilerinin birbirinden farkl� olmas� nedeniyle �ok
�nemlidir. Bu ama�la acilde uygulanmas� gereken g�r�nt�leme y�ntemi kranyal
bilgisayarl� tomografidir (BT). Kranyal BT yaln�zca kanamayla iskemiyi
ay�rdetmekle kalmay�p inmeye ba�l� geli�ebilecek n�rolojik komplikasyonlara ait
radyolojik de�i�ikliklerin tan�nmas�n� ve inme ile kar��abilecek di�er hastal�k
s�re�lerinin d��lanmas�n� da sa�layacakt�r. Hastalar�n bu incelemeye
g�nderilmeden �nce mutlaka solunum, hemodinamik ve metabolik a��dan vital
fonksiyonlar� g�vence alt�na al�nm�� olmal�d�r. Bu incelemenin hemen yap�lmas�
gerekiyorsa destek tedavilerinin bu inceleme esnas�nda hastaya e�lik edilerek
paralel bir �ekilde s�rd�r�lmesi gerekmektedir. Kranyal BT acilde kontrasts�z
yap�lmal�d�r. Akut d�nemde BT gerek subaraknoid gerekse de beyin parenkimi
i�ine kanamay� g�steren en duyarl� y�ntemdir. Kanama parenkim i�inde ise BT'de
hiperdens bir kitle olarak g�r�l�r (bak�n�z: <a
href="http://www.itfnoroloji.org/svh/kanama.htm">Beyin Kanamas�</a> ). �skemik
inmenin ba�lang�c�ndan sonra ne kadar uzun s�re ge�mi�se kranyal BT'de bunun
lezyon kar��l���n� g�rme �ans� o kadar artar. Serebral gri madde ile ak madde
aras�ndaki kontrast�n azalmas�, yani gri madde ile ak madde aras�ndaki anatomik
s�n�rlar�n�n g�r�nmez hale gelmesi kontrasts�z BT'de iskeminin ilk belirtisidir
ve inmenin ba�lang�c�ndan sonraki ilk 3 saatte saptanabilir. Bu de�i�iklik en
kolay derin bazal ganglia yap�lar�nda (<b>�ekil 1</b>) ve korteks serebride
izlenebilir. Arteryel infarkt�n g�r�nt�s� belirli bir arter sulama alan�nda
ortaya ��km�� hipodens bir lezyondur (<b>�ekil 2</b>), ven�z infarktlar ise
belirli bir arter sulama alan� d���na ta�arlar ve genellikle erkenden hemorajik
�zellik ta��rlar (Bak�n�z: <u><span style='color:#1F497D'><a
href="venoztromboz.htm">Ven�z Trombozlar</a></span></u>). Akut iskemik inmede
hastalar�n yakla��k %50'sinde inceleme normal olarak bulunur. Bu durumda klinik
bulgular inme ile uyumluysa iskemik inme tan�s� konulur. Bu tan� daha ge� d�nemde
(24 ile 72 saat sonra) ya BT ya da di�er bir g�r�nt�leme y�ntemi ile
kesinle�tirilir. Kranyal BT'de iskemi hemoraji ayr�m� yap�ld�ktan sonra kitle
etkisi (<b>�ekil 3</b>), hidrosefali, hemorajik transformasyon (<b>�ekil 4</b>)
gibi n�rolojik komplikasyonlara ait bulgular da de�erlendirilir. Bilgisayarl�
tomografi erken d�nem i�in yeterli bir g�r�nt�leme y�ntemi olmakla birlikte,
&nbsp;uygun sekanslar kullan�larak yap�lan magnetik rezonans g�r�nt�leme
incelemesinde &nbsp;BT ile elde edilen bilgiler elde edildi�i gibi ek baz�
bilgilere de ula��labilir. Kana duyarl� magnetik rezonans g�r�nt�leme
sekanslar� (T2*GRE -gradient recalled echo) kullan�larak &nbsp;iskemi/kanama
ay�r�m� yap�labilir (bak�n�z: <u><span style='color:#3366FF'><a
href="kanama.htm">Beyin Kanamas�</a></span></u> ) &nbsp;Dif�zyon a��rl�kl�
g�r�nt�leme ile iskemik beyin b�lgesi ilk<span style='color:red'> </span>dakikalardan
itibaren belirlenebilir. <span style='color:#002060'>Dif�zyon</span> ve
perf�zyon a��rl�kl� incelemeler birlikte de�erlendirilerek iskemik penumbra
b�lgesine&nbsp; ait bilgiler elde edilebilir. Bu nedenlerle klinik durumu MR incelemesine
uygun olan hastalarda yukardaki MR sekanslar� zaman kayb�na yol a�madan
uygulanabiliyorsa magnetik rezonans g�r�nt�leme bilgisayarl� tomografinin
yerini alabilir. &nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;line-height:normal;
punctuation-wrap:simple;text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;color:#0070C0;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/svh/ted1.jpg"><b><span style='color:#0070C0'>�ekil
&nbsp;1.</span></b></a></span><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;color:#002060;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/svh/ted1.jpg"><b><span style='color:windowtext'>&nbsp;</span></b></a></span><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Solda
n. caudatus ve putamenin konturlar�n�n silinmi� oldu�u g�r�l�yor (ok).</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;line-height:normal;
punctuation-wrap:simple;text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;color:#0070C0;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/svh/ted2.jpg"><b><span style='color:#0070C0'>�ekil
2.</span></b></a></span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'> Sol a. serebri media sulama alan�nda derin yap�lar� da
ilgilendiren infarktla uyumlu geni� hipodens alan g�r�l�yor (oklar). </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;line-height:normal;
punctuation-wrap:simple;text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;color:#0070C0;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/svh/ted3.jpg"><b><span style='color:#0070C0'>�ekil
3.</span></b></a></span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'><a href="http://www.itfnoroloji.org/svh/ted3.jpg"><span
style='color:windowtext'> </span></a>Solda a. serebri media sulama alan�n�n
t�m�n� ilgilendiren geni� infarkt alan� g�r�l�yor. �nfarkt sol yan ventrik�le
bas� yapmakta ve arta hat yap�lar�n� sa�a do�ru itmekte.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;line-height:normal;
punctuation-wrap:simple;text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;color:#0070C0;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/svh/ted4.jpg"><b><span style='color:#0070C0'>�ekil
4.</span></b></a><a href="http://www.itfnoroloji.org/svh/ted4.jpg"><span
style='color:#0070C0'>&nbsp; </span></a></span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Geni� sol a. serebri media
infarkt�n�n hemorajik transformasyonu&nbsp; </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:72.0pt;margin-bottom:.0001pt;line-height:150%;layout-grid-mode:
char;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><b><span lang=TR style='font-size:13.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><b><span lang=TR style='font-size:13.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>Acilde yap�lmas�
gereken di�er tan� ama�l� incelemeler nelerdir? </span></b><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>(<b>Tablo 2</b>)</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><span lang=TR style='font-size:13.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><a href="http://www.itfnoroloji.org/svh/inmetedavi2.htm"><b><span
style='font-size:10.0pt'>Tablo 2.</span></b></a></span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Akut inmeli
hastada tan� incelemeleri</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�skemik inmeye yol a�an
nedene y�nelik ilk bilgileri toplamak ve inme seyrinde ortaya ��kabilecek akut
medikal komplikasyonlar� ortaya koymak amac�yla her hastada klinik
de�erlendirme d���nda baz� laboratuar muayeneleri yap�lmal�d�r. Kalb ve iskemik
inme aras�ndaki s�k� etyolojik ili�kinin yan� s�ra inme sonras� erken d�nem
kardiyopulmoner komplikasyonlar da g�z �n�nde bulundurularak her inmeli hastada
EKG ve akci�er grafisi �ekilmelidir. Tablo 1�de listelenmi� kan incelemeleri
tipi ne olursa olsun inmeye e�lik eden ciddi komorbid durumlar�, medikal
komplikasyonlar� ortaya koymak amac�yla �nemlidir. Hipoglisemi inmeyi taklit
edebilecek akut fokal n�rolojik defisit ile ortaya ��kabilece�inden erkenden
h�zl�ca tan�nmal�d�r. Bu ama�la parmak ucundan kapiler kan �ekerine bak�lmas�,
b�ylece ven�z kan sonu�lar� gelene kadar tedavi i�in zaman kaybedilmemesi
gerekmektedir. Koag�lasyon testleri hemorajik inmenin yan� s�ra&nbsp; iskemik
inmeye yol a�abilecek olas� bir hematolojik hastal���n varl��� hakk�nda bilgi
verebilir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Acilde beyin omurilik
s�v�s� (BOS) incelemesi hastada ancak subaraknoid kanama d���n�l�yorsa ve
kranyal bilgisayarl� tomografi ile &nbsp;tan� konulamam��sa yap�lmal�d�r. Bu
inceleme herniasyona yol a�ma riski<b> </b>ta��d���ndan klinik veya g�r�nt�leme
incelemeleri kitle etkisine yol a�m�� geni� bir lezyon varl���n� d���nd�r�yorsa
yap�lmamal�d�r. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><b><span lang=TR style='font-size:13.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><b><span lang=TR style='font-size:13.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>�skemik inmeli
hastada hastaneye yatt�ktan ve stabilizasyon sa�land�ktan sonra yap�lacak
ikincil tan�sal de�erlendirmenin ama�lar� nelerdir?</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><b><span lang=TR style='font-size:13.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Hasta acil olarak
de�erlendirildikten ve izlenmek amac�yla hastaneye yat�r�ld�ktan sonra daha
ayr�nt�l� bir anamnez al�nmal� ve daha geni� bir sistemik ve n�rolojik muayene
yap�lmal�d�r. Bu d�nemde yap�lacak incelemeler inmenin nedenini ortaya koymaya,
vask�ler risk fakt�rlerini saptamaya ve b�ylece de inmeden ikincil koruyucu
tedavilerin belirlenmesine y�neliktir. Bu ama�la baz� olgularda beyni daha
ayr�nt�l� olarak g�r�nt�leyebilme �zelli�i olan kranyal MRG, ve genel olarak
t�m hastalarda da inme etyolojisini ara�t�rmak amac�yla beyin damar ve kardiyak
g�r�nt�leme incelemeleri yap�l�r. Yine se�ilmi� olgularda koag�lopati taramas�
bu d�nemde yap�lacak incelemeler aras�ndad�r (bak�n�z: <a
href="http://www.itfnoroloji.org/svh/gencinme.htm">Gen�lerde �nme </a>).</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Magnetik Rezonans G�r�nt�leme</span></i></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Magnetik rezonans
g�r�nt�leme (MRG) incelemesi iskemik lezyonlar� g�r�nt�lemede kranyal
bilgisayarl� tomografiden daha duyarl� bir y�ntemdir. �zellikle arka �ukur
yap�lar�, beyin sap�ndaki iskemik lezyonlar (<b>�ekil 5</b>), lak�ner
infarktlar bu inceleme ile daha kolayl�kla g�r�nt�lenebilir (<b>�ekil 6</b>).
&nbsp;Dif�zyon a��rl�kl� g�r�nt�leme (DWI-diffusion weighted image)&nbsp;
sekans� ile iskemik lezyonlar ilk dakikalardan itibaren g�venilir bir �ekilde
belirlenebilir (<b>�ekil 7</b>). Bu sekans g�r�nt�leme ile iskemik lezyon
belirlemenin duyarl���n� �nemli �l��de artt�rm��t�r. �zellikle k���k kortikal
&nbsp;infarktlar ile derin ak maddedeki nonspesifik sinyal de�i�ikleri
nedeniyle di�er MR sekanslar�nda fark edilmeleri g�� olan k���k derin
&nbsp;infarktlar bu y�ntemle akut d�nemde �ok daha kolay tan�nabilmektedir
&nbsp;(<b>�ekil 8</b>) Kana duyarl� magnetik rezonans g�r�nt�leme sekanslar�
(T2*GRE -gradient recalled echo) intraserebral kanamalar� y�ksek bir
duyarl�l�kla g�sterir. &nbsp;B�ylece akut d�nemde MR ile iskemi/kanama ayr�m�
yap�labildi�i gibi, sessiz serebral mikrokanama odaklar� da belirlenebilir.
Perf�zyon a��rl�kl� g�r�nt�leme (PWI- perfusion weighted image) ile beyinde kan
ak�m�n�n azald��� b�lgeler saptanabilir. Kal�c� infarkt�n belirteci olan
dif�zyon lezyonu ile perf�zyon defekti g�steren b�lge aras�ndaki fark,
s�regelen penumbra b�lgesinin varl���na yakla��k olarak i�aret edebilir&nbsp; (<b>�ekil
9</b>).</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;line-height:normal;
punctuation-wrap:simple;text-autospace:none'><span lang=TR style='font-family:
Tahoma;color:#339966;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;line-height:normal;
punctuation-wrap:simple;text-autospace:none'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:#0070C0;mso-ansi-language:
TR'><a href="ted5.jpg">�ekil 5<span style='font-weight:normal'>.</span></a></span></u></b><u><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;color:#0070C0;mso-ansi-language:
TR'> </span></u><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Sol basis pontis d�zeyinde infarkt alan�.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;line-height:normal;
punctuation-wrap:simple;text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-align:justify;line-height:normal;
punctuation-wrap:simple;text-autospace:none'><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/svh/ted6.jpg"><b><span style='color:#0070C0'>�ekil
6.</span></b><b><span style='color:windowtext'> </span></b></a>Solda korona
radiata d�zeyinde lak�ner infarkt (oklar).</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal;layout-grid-mode:
char;punctuation-wrap:simple;text-autospace:none'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:#0070C0;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal;layout-grid-mode:
char;punctuation-wrap:simple;text-autospace:none'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:#0070C0;mso-ansi-language:
TR'><a href="ted7.jpg">�ekil 7.</a></span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:#C0504D;mso-ansi-language:
TR'>&nbsp; </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Sol MCA sulama alan�nda akut infarkt�n erken d�nemde T2
a��rl�kl� incelemede (T2WI) se�ilemezken dif�zyon a��rl�kl� incelemede&nbsp;
(DWI) g�r�n�m�. A)T2WI&nbsp; normal, B) DWI&nbsp; iskemik lezyon alan�
hiperintens, C) Ayn� b�lge ADC haritas�nda hipointens<span style='color:#C0504D'>.</span></span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal;layout-grid-mode:
char;punctuation-wrap:simple;text-autospace:none'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:#0070C0;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal;layout-grid-mode:
char;punctuation-wrap:simple;text-autospace:none'><b><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:#0070C0;mso-ansi-language:
TR'><a href="ted8.jpg">�ekil 8.</a></span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;color:#0070C0;mso-ansi-language:
TR'>&nbsp; </span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Akut inmeli hastada&nbsp; MR g�r�nt�leme. FLAIR a��rl�kl�
kesitlerde periventrik�ler ak madde hiperintens oldu�u i�in inmeden sorumlu
iskemik lezyona karar verilemeyen hastada (A) dif�zyon a��rl�kl� MR
g�r�nt�lemede korona radiyatada taze iskemik lezyonun g�r�n�m� (B). </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;color:#0070C0;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><b><u><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;color:#0070C0;mso-ansi-language:TR'><a href="ted9.jpg">�ekil
9<span style='font-weight:normal'>.</span></a></span></u></b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;&nbsp;
Akut iskemik inmede dif�zyon&nbsp; a��rl�kl� (DWI) ve perf�zyon a��rl�kl� (PWI)
MR g�r�nt�leri.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>Soldaki resimde&nbsp; sa� MCA sulama alan�nda
taze&nbsp; iskemik lezyona ait dif�zyonun k�s�tland��� b�lge g�r�l�yor.Ayn�
zamanda yap�lan perf�zyon incelemesindeise MCA alan�ndaki perf�zyon defektinin
DWI ile saptanan alandan daha geni� oldu�u g�r�l�yor. Bu iki g�r�nt� aras�ndaki
b�lgenin iskemik penumbra alan�n� yans�tt��� d���n�l�yor<span style='color:
#339966'>.</span></span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;color:red;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Beyin Damar G�r�nt�lemeleri</span></i></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Beyin damarlar� bir�ok
y�ntemle incelenebilir. Bu y�ntemlerin uygulama zamanlar� ve indikasyonlar�
birbirinden farkl�d�r. Boyun renkli Doppler ultrasonografi incelemesi
ekstrakranyal karotis ve vertebral arterleri inceleme amac�yla yayg�n �ekilde
ba�vurulan non invaziv bir incelemedir. Deneyimli ellerde karotis komunis
bif�rkasyonu, karotis interna orijini ve vertebral arter orijini d�zeyindeki
aterosklerotik darl�klar� veya t�kanmalar� g�r�nt�leyebilir&nbsp; <b>(�ekil
10).</b> Bu inceleme iyi bir tarama testidir ve sonu�lar� ileri bir darl��a
i�aret ediyorsa magnetik rezonans anjiografi (MRA), bilgisayarl� tomografik
anjiografi (BTA) (<b>�ekil 11</b>) veya dijital subtraksiyon anjiyografi (DSA)
(<b>�ekil 12</b>) ile do�rulanabilir. Ultrasonografik inceleme ile karotis
interna ve vertebral arterlerin ekstrakranyal disseksiyonlar� da ortaya
konulabilir. �ntrakranyal arterler transkranyal Doppler (TKD), transkranyal
renkli Doppler (TKRD), MRA, BTA<s> </s>ve DSA incelemeleri ile ara�t�r�l�r.
Transkranyal ultrasonografik incelemeler incelemeyi yapan ki�iye ba�l� ve
deneyim gerektiren incelemelerdir. �yi uyguland���nda arteryel yap�lar�n
incelenmesinde verimli bir tarama y�ntemidir . �ntrakranyal arterler MRA (<b>�ekil
13</b>) ve BTA ile kolayl�kla non invaziv bir �ekilde g�r�nt�lenebilir. Dijital
subtraksiyon anjiyografi tan� ve giri�imsel n�roradyolojik tedaviler amac�yla
yap�lan invaziv bir incelemedir. Bu inceleme halen ekstra ve intrakranyal
damarlar�n en do�ru �ekilde incelemesine olanak sa�layan y�ntemdir. Ancak
invaziv bir y�ntem olmas� ve komplikasyon riski ta��mas� kullan�m alan�n�
s�n�rlar. Genellikle intrakranyal kanamal� olgularda anevrizma, arterio-ven�z
malformasyon gibi patolojilerin ara�t�r�lmas�nda ba�vurulan ilk incelemedir
(bak�n�z: <a href="http://www.itfnoroloji.org/svh/kanama.htm">Beyin Kanamas�</a>
). Di�er durumlarda, e�er elde edilecek bulgular tedavi giri�imlerinde bir
de�i�ikli�e yol a�acak ve yap�lm�� non invaziv damar incelemeleri yeterli sonu�
vermemi�se DSA uygulan�r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><a href="ted10.jpg"><b><span style='font-size:10.0pt'>�ekil 10.</span></b></a><a
href="http://www.itfnoroloji.org/svh/ted7b.jpg"><span style='font-size:10.0pt'>
</span></a></span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;
mso-ansi-language:TR'>Bulbusta B-mode incelemede aterosklerotik plaklara ba�l�
darl�k. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal;layout-grid-mode:
char;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal;layout-grid-mode:
char;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="ted11.jpg"><b>�ekil 11.</b></a> Kranyoservikal damarlar�n bilgisayarl�
tomografi ile yap�lan anjiyografide (BT anjiyografi) g�r�nt�lenmesi.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal;layout-grid-mode:
char;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Solda: Karotis
interna ba�lang�c�nda ileri derecede segmenter darl�k.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:35.4pt;margin-bottom:.0001pt;line-height:normal;layout-grid-mode:
char;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sa�da: Karotis
interna ��k�� b�lgesinde&nbsp; aterom pla��nda kalsifikasyon ile arterom
pla��n�n neden oldu�u darl�k ve �eper d�zensizli�i g�r�l�yor</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;color:#339966;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;color:#0070C0;
mso-ansi-language:TR'><a href="ted12.jpg"><b><span style='font-size:10.0pt;
color:#0070C0'>�ekil 12.</span></b></a></span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Dijital subtraksiyon
anjiografisinde sol karotis interna ba�lang�c�nda ileri darl�k g�r�l�yor.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;color:#0070C0;
mso-ansi-language:TR'><a href="ted13.jpg"><b><span style='font-size:10.0pt;
color:#0070C0'>�ekil 13a.</span></b></a></span><span lang=TR style='font-size:
10.0pt;font-family:Tahoma;color:#339966;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�ntrakranyal
MRA incelemesinde her iki karotis interna supraklinoid b�lge (iki ok), a.
serebri media M1 (kal�n oklar) ve M2 segmenti (ince oklar) ve a. serebri
anteriorlar (ok ba�lar�) g�r�lmekte.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;color:#339966;
mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;color:#0070C0;
mso-ansi-language:TR'><a href="ted13b.jpg"><b><span style='font-size:10.0pt;
color:#0070C0'>�ekil 13b</span></b></a></span><span lang=TR style='font-family:
Tahoma;color:#339966;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/svh/ted11b.jpg"><span style='font-size:10.0pt;
color:#339966'>.</span></a></span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;color:#339966;mso-ansi-language:TR'> </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Baziler arter
(kal�n ok), superior serebellar arterler (ok ba��lar�) ve posterior serebral
arterler (ince oklar) g�r�lmekte. c�de her iki vertebral arterin V4 segmentleri
(ince oklar) g�r�l�yor.( 11a ve b birle�tir)</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kalb hastal�klar� ve
kalb kaynakl� emboli iskemik inmenin �nemli bir nedeni oldu�undan bir�ok
hastada kardiyak g�r�nt�leme incelemeleri yap�l�r. Transtorasik veya
trans�sofagial ekokardiyografi bu ama�la en s�k ba�vurulan incelemelerdir.
Transtorasik ekokardiyografi sol ventrik�l� ilgilendiren patolojileri (miyokard
infarktusuna ba�l� duvar hareket bozukluklar�, anevrizma, mural tromb�s vs)
ara�t�rmak i�in uygun bir y�ntemdir. Trans�sofagial ekokardiyografi sol atrium
ve appendiksini (atrial tromb�s), interatrial septumu (patent foramen ovale,
atrial septal anevrizma vs), mitral kapa�� incelemek i�in en duyarl�
incelemedir. Ate� ve iskemik inme nedeniyle ba�vuran hastalarda olas� bir
bakteryel endokardit tan�s�n� koyabilmek amac�yla bu incelemeler acil olarak
yap�lmal�d�r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Damar ve kardiyak
g�r�nt�leme incelemeleriyle belirgin bir etyolojik neden ortaya konulamayan
hastalarda koag�lopati incelemeleri yap�labilir. Bu testler �zellikle gen�
ya�ta iskemik inme ge�irenlerde, �zge�mi�inde veya soyge�mi�inde nedeni
bilinmeyen tekrarlay�c� arteryel veya ven�z tromboembolik olay anamnezi
olanlarda (iskemik inme, MI, derin ven trombozu, pulmoner emboli), livedo
retik�larisi olanlarda, sistemik lupus eritematosus �yk� veya klinik bulgular�
olan hastalarda mutlaka yap�lmal�d�r (bak�n�z: <a
href="http://www.itfnoroloji.org/svh/gencinme.htm">Gen�lerde �nme </a>).
�nflamatuar (vask�lit) veya infeksiy�z nedenlerden ��phelenildi�inde BOS
incelemesi en iyi tarama testidir. </span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�nmenin etyolojik
incelemelerinin yan�s�ra her hastada vask�ler risk fakt�rleri ara�t�r�lmal�d�r.
Bu ama�la mutlaka her hastada a�l�k kan �ekeri ve lipid incelemeleri
(kolesterol, trigliserid, HDL kolesterol, LDL kolesterol, VLDL kolesterol)
yap�lmal�d�r. Diyabetik hastalarda kan �ekeri reg�lasyonu hakk�nda fikir
edinmek i�in glikozile hemoglobin (HbA1c) d�zeyine bak�lmal�d�r. Akut d�nemde
bak�lan lipid d�zeylerinin d���k ��kabilece�i ak�lda tutulmal�, d�zeyler
normalse bu incelemeler 6-12 hafta sonra tekrarlanmal�d�r</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><b><span
lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><b><span
lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>TEDAV�</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><b><span
lang=TR style='font-size:14.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><b><span lang=TR style='font-size:13.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>�skemik inmeli
hastaya acil tedavi yakla��m�n ama�lar� nelerdir?</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�nmeli hastalarda acil tedavi
uygulamalar� ilk g�r�ld�kleri andan itibaren ba�lamal�d�r. �ster iskemik
isterse de hemorajik olsun hastane �ncesi ve hastaneye transport s�ras�nda
uygulanacak en �nemli giri�imler vital parametreleri g�vence alt�na almaya y�neliktir.
Bu m�dahaleler acil servislerinde n�roloji kons�ltasyonu yap�lana ve hasta
uygun bir n�roloji yata��na yat�r�lana dek s�rd�r�lmelidir. Acilde ayr�ca bu
d�nemde erken n�rolojik ve medikal komplikasyonlar�n tedavilerine
ba�lanmal�d�r. Her inmeli hasta m�mk�nse hastaneye yat�r�lmal�d�r. Hastanede
koroner yo�un bak�mlara benzer �ekilde yaln�zca inmeli hastalara bak�m ve
tedavi hizmeti veren �inme �niteleri� bulunuyorsa bu tip yataklar tercih
edilmelidir. Son y�llarda yap�lan �al��malar inme konusunda uzmanla�m�� bir
doktor, hem�ire, yard�mc� sa�l�k personeli i�eren ve multidisipliner bak�m
verebilen inme �nitelerine yat�r�lan hastalarda akut d�nemde olgu �l�m oran�
d��t���, uzun vadede de hastalar�n sakatl�k oranlar�n�n azald���
g�sterilmi�tir.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�skemik inmeli hastan�n
hastaneye yat�r�lmas�ndaki ama�lar a�a��daki gibi �zetlenebilir. Bu tipi ne
olursa olsun t�m inmeli hastalar i�in ge�erlidir:</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
normal'><span lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<ul style='margin-top:0cm' type=disc>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
     normal;mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span lang=TR
     style='font-family:Tahoma;mso-ansi-language:TR'>Vital bulgular� stabilize
     etmek </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
     normal;mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span lang=TR
     style='font-family:Tahoma;mso-ansi-language:TR'>N�rolojik hasar� durdurmak
     veya geriye d�n���ml� ise d�zeltmek</span><span lang=TR style='mso-ansi-language:
     TR'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
     normal;mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span lang=TR
     style='font-family:Tahoma;mso-ansi-language:TR'>�nme ile beraber veya
     seyrinde ortaya ��kacak medikal ve n�rolojik komplikasyonlarla m�cadele
     etmek</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
     normal;mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span lang=TR
     style='font-family:Tahoma;mso-ansi-language:TR'>Erken d�nemden ba�lamak
     �zere rehabilitasyon giri�imlerini ba�latmak</span><span lang=TR
     style='mso-ansi-language:TR'><o:p></o:p></span></li>
 <li class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
     normal;mso-list:l1 level1 lfo2;tab-stops:list 36.0pt'><span lang=TR
     style='font-family:Tahoma;mso-ansi-language:TR'>Erken d�nemde hasta
     ailesinin yeni duruma adaptasyonunu sa�lamak i�in bilgilendirme ve destek
     sa�lamakt�r</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:normal;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></i></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Vital bulgular� stabilize etmek </span></i></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><b><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Hastane �ncesi d�nemde destek tedavi yakla��mlar� </span></b><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>(Tablo 3)</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><a href="http://www.itfnoroloji.org/svh/inmetedavi3.htm"><b><span
style='font-size:10.0pt'>Tablo 3.</span></b><span style='font-size:10.0pt'> </span></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;Akut
inmeli hastada hastane �ncesi d�nemde destek tedavi yakla��mlar�<b> </b></span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><b><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Akut inmeli hastan�n
hastaneye ula�t�r�lmas� tedavi ba�ar�s�n� etkileyecek en �nemli ara basamakt�r.
Akut inmeli hasta akut miyokard infarkt�s� veya travma hastas� gibi ele
al�nmal�d�r. Hasta bulundu�u yerden hastaneye h�zl�ca ta��n�rken ayn� zamanda
destek tedavileri de ba�lat�lmal�d�r. �skemik inmenin erken saatlerinde beyin
dokusunun bir b�l�m� �lm�� olsa bile bir�ok hastada risk alt�nda olan ancak
hala ya�am�n� s�rd�ren �penumbra� dokusunun (bak�n�z: <a
href="http://www.itfnoroloji.org/svh/anatomofizyoloji.html">Beyin Kan
Dola��m�n�n Anatomi ve Fizyolojisi</a>) gelece�i bir �l��de bu destek
tedavisinin ba�ar�s�na ba�l�d�r. Her t�rl� acil durumda oldu�u gibi temel ve
ileri ya�am deste�i tedavileri uygulanacakt�r. Bu erken d�nemde doku
oksijenasyonu ve hemodinaminin optimal d�zeyde tutulmas�, hipogliseminin
d�zeltilmesi ya�amsal �nem ta��r. Hava yolu a��kl��� sa�lanmal�, hipoventile
eden hastalarda gerekirse mekanik solunum deste�i verilmeli ve ampirik olarak
2-3 lt/dakika O2 tedavisine ba�lanmal�d�r. Hava yolu a��kl���n�n sa�lanmas� ve
bunun korunmas� �zellikle aspirasyon riski y�ksek olan uyan�kl��� bozuk veya
kusan hastalarda �ok �nemlidir. Dehidratasyon �nlenmeli, saptanm��sa tedavi edilmelidir.
Bu ama�la damar yolu a��lmal� ve izotonik sodyum klor�r veya Ringer laktat
sol�syonu ile parenteral s�v� tedavisine ba�lanmal�d�r. Akut d�nemde
hipoglisemi saptanmad�k�a dekstrozlu s�v� verilmemelidir. Hemodinamiyi bozan
supra veya ventrik�ler aritmiler tedavi edilmelidir. Bir�ok inmeli hastada akut
d�nemde saptanan y�ksek kan bas�nc� akut miyokard infarkt�s�, akci�er �demi,
akut b�brek yetmezli�i ve aort disseksiyonu ��phesi gibi bir hipertansiyon
acili ile kar�� kar��ya de�ilsek rutin olarak tedavi edilmemelidir (<b>Tablo 4</b>).
Kan bas�nc�na rutin m�dahale serebral perf�zyon bas�nc�n�n d��mesine
dolay�s�yla da infarkt dokusu ve �evresindeki b�lgesel kan ak�m�n�n azalmas�na
yol a�abilir.<b>Tablo 4</b>�ten anla��laca�� gibi transport esnas�nda kan
bas�nc�na y�nelik m�dahale olanaklar� s�n�rl�d�r<span style='color:red'>. </span><span
style='color:black'>Bu d�nemde bulant�</span> kusma, a�r� gibi sorunlarla
m�cadele edilebilir. Yine bu d�nemde ate�i y�ksek olan hastalarda so�uk
uygulama ve antipiretiklerle ate� d���r�lmeye �al���lmal�d�r. Konv�lsiyon
ge�iren hastan�n n�beti durdurulmal�d�r.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><a href="http://www.itfnoroloji.org/svh/inmetedavi4.htm"><b><span
style='font-size:10.0pt'>Tablo 4.</span></b></a></span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Akut inmeli
hastada hipertansiyona yakla��m�n prensipleri</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><b><span lang=TR style='font-size:12.0pt;
font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><b><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><b><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Acil Serviste destek tedavi yakla��mlar� </span></b><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>(<b>Tablo 5</b>)</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><a href="http://www.itfnoroloji.org/svh/inmetedavi5.htm"><b><span
style='font-size:10.0pt'>Tablo 5.</span></b></a></span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Akut inmeli
hastada Acil Serviste destek tedavi yakla��mlar�</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Hasta acile
getirildikten sonra acil tan�sal de�erlendirmelerin yap�ld��� s�re boyunca
hastane �ncesinde ba�lanm�� olan destek tedavileri s�rd�r�lecektir. Acil
servislerinde ideal olan� hastalar�n vital parametrelerinin s�rekli olarak
monitorize edilmesi ve tedavilerin bu monitorizasyon bulgular�na g�re
�ekillendirilmesidir. Bu d�nemde ate�i y�ksek olan hastalarda s�rmekte olan
olas� bir infeksiyona y�nelik vucut s�v�s� �rnekleri al�nd�ktan sonra ampirik
antibiotik tedavisine ba�lanabilir. Ate�li bir tablo seyrinde inme ile ba�vuran
hastalarda acil olarak ekokardiyografik incelemelerle bakteryel endokardit ara�t�r�lmal�
ve pozitif bulgular varl���nda ampirik antibiotik tedavi buna g�re
d�zenlenmelidir. Kan �ekeri y�ksek bulunan hastalarda genellikle 200 mg/dl�nin
�st�nde ins�lin tedavisine ba�lan�r. Hasta diabetik ve oral antidiabetik
ila�lar al�yorsa bunlar durdurulur. �nmenin erken d�neminde<b> </b>oral
beslenmeden ka��nmal�d�r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>�skemik inmede n�rolojik hasar� durdurmak veya geriye d�n���ml� ise
d�zeltmek</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><b><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><b><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Semptomatik medikal tedaviler</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Hastan�n hastaneye
transportu s�ras�nda ba�lat�lan ve acilde s�rd�r�len medikal destek tedavileri
ayn� zamanda n�rolojik hasar�n artmas�n� �nlemeye y�nelik bir anlamda �beyin
resusitasyonunu� sa�layan giri�imlerdir. Bu medikal destek yakla��mlar�n�n yan�
s�ra inmenin ba�lang�c�nda konv�lsiyon ge�irmi� hastalarda veya konv�lsiyon ge�iren
hastalarda parenteral antiepileptik tedaviye ba�lanmal�d�r. Ayr�nt�l� n�rolojik
de�erlendirme ve beyin g�r�nt�leme incelemeleri e�er artm�� kafa i�i bas�nc�na
ve herniasyon riskine i�aret ediyorsa h�zla kafa i�i bas�nc�n� d���r�c�
tedaviler uygulanmal�d�r (<b>Tablo 5</b>).</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><b><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><b><span lang=TR
style='font-size:13.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Spesifik tedaviler</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><b><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><b><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Akut iskemik inmede spesifik medikal tedaviler </span></b><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Beyni besleyen bir
damar�n tromboembolik mekanizmayla t�kanmas� ve bu damar�n besledi�i dokunun
kan ak�m�n�n kesintiye u�ramas� iskemik inmeye yol a�an en �nemli nedendir. Bu
nedenle ba�lam�� doku hasar�n�n durdurulmas� b�lgesel kan ak�m�n�n yeniden
sa�lanabilmesi ile olanakl�d�r. Bu ama�la trombolitik, antikoag�lan ve
antiplatelet tedavilere ba�vurulur. Son y�llarda bu tedavi y�ntemleri ile geni�
hasta topluluklar�nda �nemli �al��malar yap�lm��t�r. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>Trombolitik
tedavi</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Doku plasminojen
aktivat�r� ile intraven�z yolla yap�lan trombolitik tedavi iskemik inmenin ilk
3 saatinde uygulan�rsa hastalar�n prognozlar�nda iyile�meye yol a�ar. Bu
tedavinin uyguland��� hastalarda 3. ayda sakatl�k oran� azal�r. Ancak bu tedavi
erken d�nemde beyin kanamas� riskini ve buna ba�l� �l�m riskini artt�rmaktad�r.
Bu nedenle yaln�zca inme konusunda uzman ve iyi organize edilmi� kurumlarda
indikasyon ve kontrendikasyonlar� (<b>Tablo 6</b>) ayr�nt�l� bir �ekilde g�zden
ge�irildikten sonra uygulanmal�d�r. Tedavi indikasyonunun inmenin ilk 3 saati
olmas� erken d�nemde inme �n tan�s� olan hastalar�n hastaneye h�zl�ca ula�t�r�lmas�n�n
ne kadar �nemli oldu�unu g�stermektedir.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Iskemik inmenin ilk 3
saatinde tromboliz tedavisi uygulamak zordur. Bir�ok hasta 3 saatten daha ge�
hastaneye ula�maktad�r. Bu nedenle 3-6 saat aras�nda da etkili olabilecek
tedavilere ihtiya� vard�r. �ntraven�z trombolitik tedavinin yarar�n�n 4,5 saate
dek s�rd���n� ve arteria serebri media alan� inmelerinde ilk 6 saatte yap�lan
intraarteriyel trombolizin yararl� oldu�unu g�steren �al��malara dayanarak bu
uygulamalar�n yap�labilece�i y�n�ndeki �neriler 2009 y�l�nda yenilenen inme
tedavi rehberlerine girmi� olmakla birlikte, trombolitik tedavinin bu
indikasyonlarla uygulanmas� hen�z Avrupa �lkeleri ve T�rkiye de
ruhsatland�r�lm�� de�ildir. Radyolojik y�ntemlerle 3-6 saatin �tesi de dahil
olmak �zere penumran�n s�regeldi�i g�sterilen hastalarda trombolitik tedavinin
yarar�n� ara�t�ran �al��malar ile intraarteriyel yoldan mekanik y�ntemlerle
t�kanmay� a�may� ama�layan �al��malar s�regelmektedir.&nbsp; </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><a href="http://www.itfnoroloji.org/svh/inmetedavi6.htm"><b><span
style='font-size:10.0pt;color:windowtext'>Tablo 6.</span></b></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> Akut
iskemik inmede trombolitik tedavi uygulama kontrendikasyonlar�</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></i><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>Antikoag�lan
tedavi </span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�skemik inmeli hastada
inmenin akut d�neminde rutin ve etkin dozda heparin veya d���k molek�l
a��rl�kl� heparinlerle antikoag�lan tedavinin yarar� olmad��� g�sterilmi�tir.
Bunun nedeni antikoag�lan tedavilerin serebral ve sistemik kanama riskini
artt�rmas� ve prognozu k�t�le�tirmesidir.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>Antiplatelet
tedavi</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Akut iskemik inmede
Aspirin tedavisinin etkinli�i g�sterilmi�tir. Aspirin tedavisi, herhangi bir
kontrendikasyon olmad�k�a, inmenin ilk 48 saatinde BT'de hemorajik inme
olas�l��� d��land�ktan sonra 160-300 mg dozunda uyguland���nda k���k de olsa
anlaml� bir yarar sa�lamaktad�r. Tedavi edilen hastalarda ilk haftalarda �l�m
veya �l�mc�l olmayan inme s�kl��� azalmaktad�r. Birka� hafta veya birka� ayl�k
bir izleme d�nemi sonunda bu tedavi ile �l�m veya sakatl�k riski azalmaktad�r .</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><i><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></i><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Akut iskemik inmede cerrahi tedaviler</span></i><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:12.0pt;line-height:150%;layout-grid-mode:
char;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>�skemik inmede cerrahi tedavi
indikasyonlar� �ok s�n�rl�d�r. Geni� serebellar infarktlar (<b>�ekil 14</b>)
beyin sap� bas�s�na yol a�arak �l�me neden olabilirler. Bu nedenle bu tip
infarktlar� olan hastalar yak�n n�rolojik takibe al�nmal�, uyan�kl��� bozulan
hastalarda beyin cerrahisi kons�ltasyonu yap�larak arka �ukur dekompresyon
cerrahisi indikasyonlar� a��s�ndan h�zl�ca de�erlendirilmelidir. Bu tip
hastalarda cerrahi m�dahale hayat kurtar�c�d�r.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:12.0pt;line-height:150%;layout-grid-mode:
char;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Arteria serebri media
alan�ndaki geni�, kitle etkisi yaratan infarktlar (malign a. cerebri media
infarkt�) % 80�e ula�an oranlarda �l�mle sonlanmaktad�r. �lk 48 saat i�inde,
18-60 ya�lar� aras�ndaki bu t�r hastalarda&nbsp; geni� kraniyektomi ve
duraplasti ile yap�lan dekompressif cerrahinin mortalite ve maluliyeti&nbsp;
azaltt��� g�sterilmi�tir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-indent:
36.0pt;line-height:150%;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/svh/ted14.jpg"><b><span style='font-size:10.0pt;
line-height:150%'>�ekil 14.</span></b></a></span><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'> Sa� serebellar hemisferde beyin sap� bas�s�na yol a�an geni� infarkt alan�
g�r�l�yor</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><b><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>�skemik inme ile beraber veya seyrinde ortaya ��kacak medikal ve n�rolojik
komplikasyonlarla m�cadele etmek</span></i></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Yukar�da inmeli
hastalar�n, �zellikle de erken d�nemde g�r�len her hastan�n hastaneye
yat�r�lmas� gerekti�ini belirttik. Bunun en �nemli nedeni inmeli hastalar�n
yakla��k %30�luk bir b�l�m�n�n ilk saat ve g�nlerde k�t�le�mesidir. Bu
hastalarda prognoz stabil olan hastalara oranla daha k�t�d�r. �nme ne kadar
a��rsa maj�r medikal ve n�rolojik komplikasyon geli�me riski de o kadar
y�ksektir. <b>Tablo 7</b>�de tipi ne olura olsun inmeyi takip eden saat ve
g�nlerde ortaya ��kabilecek n�rolojik ve sistemik komplikasyonlarla inmeli
hastalarda s�kl�kla kar��la��lan komorbid durumlar s�ralanm��t�r. Bu
komplikasyonlar ve komorbid durumlar�n hastan�n acilde g�zlenmeye ba�lad���
d�nemden ba�layarak s�rekli monitorize edilmesi ve tedavi edilmesi
gerekmektedir. <b>Tablo 8</b>�de inmeli hastan�n hastaneye yat���ndan sonraki
bak�m prensipleri �zetlenmi�tir.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><a href="http://www.itfnoroloji.org/svh/inmetedavi7.htm"><b><span lang=DE
style='font-size:10.0pt;mso-ansi-language:DE'>Tablo 7.</span></b></a></span><span
lang=DE style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:DE'>
N�rolojik ve sistemik komplikasyonlar</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><a href="http://www.itfnoroloji.org/svh/inmetedavi81.htm"><b><span
style='font-size:10.0pt'>Tablo 8.</span></b></a></span><u><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></u><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�nmeli
hastalar�n hastaneye yat���ndan sonraki bak�m ve izleme prensipleri </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Erken d�nemden ba�lamak �zere rehabilitasyon giri�imlerine ba�lamak</span></i></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�skemik inmeli
hastalarda erken d�nemden ba�lamak �zere motor rehabilitasyona ba�lanmal�d�r.
Bu b�t�n inme tipleri i�in ge�erlidir. Genellikle ilk 24 saatte yatak
istirahatine al�nan hastalar sonraki 2-3 g�n i�inde tolere edebildikleri kadar
mobilize edilmelidir. Mobilizasyon dekubitus yaras�, derin ven trombozu ve
atelektazi ve bronkopulmoner infeksiy�z komplikasyonlar�n �nlenmesinde en �nemli
yoldur. Mobilize edilecek hastalar aya�a kald�r�ld�klar�nda n�rolojik
bulgularda ortostatizme ba�l� k�t�le�me a��s�ndan izlenmeli ancak n�rolojik
durum de�i�miyorsa mobilizasyona devam edilmelidir. Bu d�nemde d��me riski
y�ksek oldu�undan yanl�z ba��na mobilizasyona izin verilmemelidir. Yata�a
ba��ml� hastalar� k�sa aral�klarla bir tarafa �evirmek, haval� yatak kullanmak
dekubitus yaras� profilaksisi a��s�ndan �nemlidir. Kontrakt�rleri ve ortopedik
komplikasyonlar� �nleyebilmek amac�yla paretik kol ve baca�a aktif veya pasif
ROM egzersizleri uygulanmal�d�r. �nmeli hastalar�n bir�o�unda akut d�nemde
yutma g��l��� vard�r, bu hastalarda beslenme ge�iktirilmemelidir. Erken d�nemde
nazogastrik sonda veya gastrostomi yoluyla enteral beslenmeye ba�vurulabir. Hi�
bir inmeli hastada yutma fonksiyonu de�erlendirilmesi yap�lmadan oral yolla
beslenmeye ba�lanmamal�d�r. Yutkunmas� bozuk olan hastalarda aspirasyon
pn�monisi prognozu ciddi bir �ekilde k�t�le�tirebilir. </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></i></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid;text-autospace:none'><b><i><span
lang=TR style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Erken d�nemde hasta ailesinin yeni duruma adaptasyonunu sa�lamak i�in
bilgilendirme ve destek sa�lamak</span></i></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�nme hasta ve ailesinde
b�y�k bir stres ve umutsuzluk yarat�r. Her�ey saniyeler i�inde olup bitmi� ve
herkez �a�k�nl�k i�indedir. Bu d�nemde aile ve hastan�n bilgilendirilmesi,
onlarla empatik bir ili�ki i�ine girilmesi b�y�k �nem ta��r. Akut d�nem sona
erdi�inde hekimin tedavide en �nemli partneri hasta ailesidir. �nme uzun
s�recek bir sakatl��a yol a�ar, bu durumda hastaya g�nl�k gereksinimlerini
kar��layabilmek i�in en b�y�k deste�i ailesi sa�layacakt�r. Aile bireylerinin
erkenden bak�m giri�imlerine dahil edilmesi uzun vadede hastal�kla
m�cadelelerini kolayla�t�racak ve verimli bir g�ven ortam� yaratacakt�r. Uzun
sakatl�k d�neminde hasta ve aile bireylerinin kar��la�t�klar� g��l�kleri
��zmede sab�rl� bir yakla��m g�stermek, ��z�m alternatifleri sunmak, gerekli
psikolojik deste�i sa�lamak inme ile u�ra�an sa�l�k personelinin �nemli bir
u�ra� alan�d�r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><b><span lang=TR style='font-size:13.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><b><span lang=TR style='font-size:13.0pt;
line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>�nmeli hastalarda
ikincil koruyucu tedavi yakla��mlar�</span></b><b><span lang=TR
style='font-size:10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'> </span></b><span lang=TR style='font-size:10.0pt;line-height:150%;
font-family:Tahoma;mso-ansi-language:TR'>(<b>Tablo 9</b>)</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;page-break-after:avoid'><span lang=TR style='font-size:13.0pt;line-height:
150%;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><a href="tanitedavi9.jpg"><b><span style='font-size:10.0pt'>Tablo 9.</span></b></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
�skemik inmede inmenin tipine g�re ikincil koruyucu tedaviler.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�skemik inme ge�iren
hastay� ikinci bir inmeden korumada aterotrombotik inme i�in antiplatelet
tedavi, kardiyoembolik inmede antikoag�lan tedavi, ekstrakranyal karotis
hastal���nda ise cerrahi tedavi, yarar� do�rulanm�� tedavi y�ntemleridir.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=TR style='font-size:
12.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>Antiplatelet
Tedavi</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�skemik damar hastal���
olan hastalarda (beyin damar, kalp damar, periferik damar) yap�lan t�m
antiplatelet tedavi �al��malar� dikkate al�narak olu�turulan tedavi �nerileri
1998 ve 1999 y�llar�nda&nbsp; yay�nlanm��t�r. Buna g�re oral antikoag�lan
tedavi indikasyonu olanlar d���nda kalan iskemik inmeli hastalarda aspirin,
klopidogrel, aspirin ve yava� sal�n�ml� dipridamol kombinasyonu gibi
antiplatelet ajanlardan birisi&nbsp; kullan�labilir. Gastrointestinal
sistemdeki olumsuz yan etkilerine ra�men kullan�m kolayl���, uzun y�llara giden
bilgi birikimi ve maliyeti nedeniyle en �ok kullan�lan antiplatelet ajan
aspirindir. Ancak �l�m ve sakatl�k riski y�ksek olan inmeli hasta grubunda
aspirinden daha etkili yeni antiplatelet ajanlar geli�tirme �abalar� ile
birlikte y�ksek riskli hastalarda kombine antiplatelet&nbsp; kullan�m�na ait
klinik �al��malar&nbsp; s�rd�r�lmektedir.Son y�llarda sekonder inmeden
korunmada aspirin ve klopidogrelin birlikte kullan�ld��� kar��la�t�rmal�
�al��malar olumsuz sonu�lanm��t�r<span style='color:red'>.</span></span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>Antikoag�lan
Tedavi</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�skemik inme ge�iren
hastalarda uzun s�reli oral antikoagulan kullan�m�n�n hastay� yeni bir inmeden
korudu�u sadece non-valv�ler atriyal fibrilasyona (NVAF) ba�l� kardiyoembolik
inme ge�iren hasta grubunda g�sterilmi�tir. Klinik �al��malar NVAF saptanan
hastalarda uzun s�reli antikoagulan kullan�m�n�n primer korunmada da yararl�
oldu�unu ortaya koymu�tur. Klinik yarar�na ra�men antikoagulan kullan�lacak
hasta grubunun iyi se�ilmesi gerekir. Tedavi s�resince hasta ve yak�nlar� ile
hekim aras�ndaki i�birli�i yan etkilerin �nlenmesi (kanama riski) a��s�ndan
�nem ta��r. Tedavi s�resince INR de�erinin 2.0-3.0 aras�nda olmas�
hedeflenmelidir. Hasta en az ayda bir kez hekim taraf�ndan&nbsp;&nbsp; kontrol
edilmelidir. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kalbinde y�ksek riskli
emboli kayna�i (romatizmal mitral stenoz, taze miyokard infarkt�s�,akinetik
segment, protez kapak, dilate kardiyomiyopati) olan ve kardiyoembolik inme
ge�iren hastalarda da bu y�nde bir klinik �al��ma olmad��� halde koruyucu
olarak antikoagulan tedavi uygulan�r.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>Cerrahi Tedavi</span></i><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Karotis
endarterektomisi karotis alan�na ait iskemik atak veya hafif sekellerle d�zelen
inme ge�iren hastalar� yeni bir inmeden koruyan bir tedavi y�ntemidir.
Tedavinin yarar� Avrupa ve Kuzey Amerikada (ECST-European Carotid Su�rgery
Trial, NASCET-North American Symptomatic Carotid Endarterectomy Trial)
y�r�t�len iki randomize �al��mada g�sterilmi�tir. Bu iki �al��mada semptomatik
karotis hastal��� olan hastalarda Kuzey Amerika �al��mas�nda kullan�lan �l�me
y�ntemi ile %50 nin �zerinde darl�k saptanan hastalar�n cerrahiden yararland���
g�r�lm��t�r. Cerrahi giri�imin yarar�, kad�nlarda daha belirgin olmak �zere
semptomlarla giri�im aras�ndaki s�re artt�k�a azalmaktad�r. Bu nedenle giri�im
olabildi�ince erken yap�lmal�d�r. �leri ya� ve erkek cinsiyet ile darl�k
derecesinin y�ksekli�i de endarterektomiden yararlanma olas�l���n� artt�ran
fakt�rler aras�ndad�r. Asemptomatik %60 �zerinde karotis darl��� saptanan
olgularin da endarterektomiden yararland��� g�r�lm��t�r. Ancak bu grupta
semptomatik karotis darl���na g�re inme riski d���k oldu�undan (y�lda %2-3
gibi) asemptomatik karotis darl��� olan &nbsp;hastalarda endarterektomiden elde
edilen &nbsp;mutlak yarar olduk�a d���kt�r. Son y�llarda karotis
endarterektomisine uygun olan hastalarda endovask�ler tedavi (balon
anjiyoplasti ve/veya �stent� (<b>�ekil 15 ve 16</b>) ile endarterektomiyi kar��la�t�ran
baz� klinik �al��malarda stent uygulamalar�n�n endarterektomiye e�de�er oldu�u
g�sterilmemi�tir. Bu konuda halen devam eden �al��malar vard�r. Anatomik veya
t�bbi nedenlerle cerrahi kontrendikasyonu olan hastalarda endovask�ler olarak
stent uygulanmas� endarterektomiye makul bir alternatif olabilir. G�n�m�zde
kar��la�t�rmal� klinik �al��malar olmad��� halde cerrahi olarak
ula��lamayan&nbsp; (a.basilaris, a.cerebri media gibi) intrakranyal
aterosklerotik darl�klara da endovask�ler tedavi y�ntemleri uygulanmaktad�r.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><a href="ted15.jpg"><b><span style='font-size:10.0pt;color:#0070C0'>�ekil
15</span></b><b><span style='font-size:10.0pt;color:windowtext'>.</span></b></a></span><b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'> </span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A)
Karotis interna bulbusunda ileri darl�k g�r�l�yor, </span><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'><a
href="http://www.itfnoroloji.org/svh/ted13b.jpg"><span style='font-size:10.0pt;
color:windowtext'>B)</span></a> </span><span lang=TR style='font-size:10.0pt;
font-family:Tahoma;mso-ansi-language:TR'>Anjiyoplasti ve stent uygulamas�
sonras�nda darl�k ortadan kalkm��.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-size:10.0pt;font-family:
Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;color:#0070C0;
mso-ansi-language:TR'><a href="ted16.jpg"><b><span style='font-size:10.0pt;
color:#0070C0'>�ekil 16.</span></b></a> </span><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span></b><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>A)
Vertebral arterin V4 segmentinde ileri dar segment g�r�lmekte, B) Anjiyoplasti
ve stent uygulamas� sonras�nda darl�k ortadan kalkm��.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=TR
style='font-size:12.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di�er Medikal
Tedaviler</span></i><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>Ge�ici iskemik atak (G�A) veya
inme ge�iren bir ki�iyi yeni bir inmeden korumada yap�lmas� gerekenlerin
ba��nda primer korunmada da ge�erli olan vask�ler risk fakt�rlerinin
belirlenmesi ve kontrol alt�na al�nmas� gelmektedir (<b>Tablo 10</b>).
Bilindi�i gibi vask�ler risk fakt�rleri ki�inin �zelliklerinden olu�an ya�,
cinsiyet, �rk-etnik ve herediter �zellik gibi de�i�tirilemeyen fakt�rler ile
de�i�tirilebilir risk fakt�rleri olarak ikiye ayr�l�r. De�i�tirilebilir risk
fakt�rleri aras�nda en ba�ta hipertansiyon, hiperlipidemi (hiperkolesterolemi,
hipertrigliseridemi), diabetes mellitus ve sigara gelmektedir. Bu risk
fakt�rleri genel anlamda toplam kardiyovask�ler morbidite ve mortalite ile
ili�kilidir. Bu risk fakt�rlerinin tedavisi primer korunmada oldu�u gibi
sekonder korunmada da y�ksek vask�ler risk ta��yan hasta gruplar�nda (koroner arter
hastal���, inme, periferik damar hastal���, diabetes mellitus) toplam
kardiyovask�ler riskin azalt�labilmesinde halk sa�l��� a��s�ndan en �nemli
basamakt�r. Son y�llarda anjiotensin konverting enzim inhibit�rleri (ACE),
statinler ve baz� fibrat t�revi ila�larla morbidite ve mortalite<span
style='color:black'>nin </span>�nemli �l��de azalt�labildi�i g�sterilmi�tir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;line-height:normal;punctuation-wrap:
simple;text-autospace:none'><span lang=TR style='font-family:Tahoma;mso-ansi-language:
TR'><a href="tanitedavi10.jpg"><b><span style='font-size:10.0pt'>Tablo 10.</span></b></a></span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>
�skemik inmeli hastalarda vask�ler risk fakt�rlerine y�nelik genel �neriler</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><b><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Antihipertansif tedavi</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Kronik hipertansiyon
t�m inme tipleri i�in ya�tan ba��ms�z de�i�tirilebilir en �nemli risk
fakt�r�d�r. Kronik hipertansiyon tedavisi gerek gen� gerekse de ya�l�
hastalarda ilk inme s�kl���nda �nemli bir azalmaya yol a�ar. Total kardiyovask�ler
morbidite ve mortalite a��s�ndan sistolik kan bas�nc�n�n optimal d�zeyi 140 mm
Hg�dir. Epidemiyolojik �al��malar primer korunmada �zellikle inme riskini
optimal d�zeyde azaltabilmek i�in 140 mm Hg'nin alt�na d��menin yararl�
olaca��n� d���nd�rtmektedir. Diyabetik hastalarda sistolik kan bas�nc�nda hedef
de�er 130 mm Hg olmal�d�r. Diastolik kan bas�nc�nda optimal d�zey ba�ta
diyabetik hastalar olmak �zere 80 mm Hg'dir. Hipertansiyon tedavisinin inme ve
koroner kalp hastal��� geli�imi a��s�ndan ortaya konulmu� yararl� etkileri
b�y�k oranda beta bloker ve di�retik ila�larla yap�lan �al��malar ile ortaya
konulmu�tur. Ancak son y�llarda di�er antihipertansif ila� gruplar� ile yap�lan
�al��malarda da benzer yararl� etkiler saptanm��t�r. �zellikle ya�l� hasta
pop�lasyonlar�nda s�k rastlanan sistolik hipertansiyonun tedavisinde uzun
etkili dihidropiridin t�revi kalsiyum kanal inhibit�rlerinin (uzun etkili
Nifedipin, Nitrendipin) yararl� etkileri g�sterilmi�tir. Antihipertansif
tedavide ACE inhibit�rleri en az�ndan beta bloker ve di�retikler kadar etkili
oldu�u ve belki de kardiyovask�ler mortaliteyi daha olumlu etkileyebilece�i
d���n�lmektedir . </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Sonu�lar� �ok yak�n
zamanda yay�nlanm�� HOPE (The Heart Outcome Prevention Evaluation Study) ve
PROGRESS (Perindopril Protection Against Reccurent Stroke Study) �al��mas�
ister do�rudan kan bas�nc�n� d���r�c� etkileri ile isterse de buna ek olarak
olas� vask�loprotektif etkileri ile olsun ACE inhibit�rlerinin ikincil korumada
iskemik veya hemorajik nat�rde tekrarlay�c� inme riskini azaltt���n�
g�stermi�tir. Bu �al��malar epidemiyolojik �al��malarla �ne s�r�len ve
antihipertansif tedavide g�n�m�zde optimal hedef olarak belirlenmi� 130/80 mm
Hg d�zeyindeki kan bas�nc� de�erlerinin tedavideki yararl�l���n� kan�tlamaktad�rlar.
</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><b><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;text-align:
justify;line-height:150%;page-break-after:avoid'><span lang=TR
style='font-size:12.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:
TR'>Hiperlipidemi tedavisi</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>�skemik kalp hastal���
ve iskemik inmenin risk fakt�rleri �nemli oranda benzerlikler g�sterir. Y�ksek
serum kolesterol, y�ksek LDL kolesterol veya d���k HDL kolesterol d�zeyleri
koroner kalp hastal���n�n en �nemli risk fakt�rleri olmas�na kar��n
epidemiolojik g�zlem �al��malar� kolesterol metabolizmas� ve inme riski
aras�nda kesin ve kuvvetli bir ili�ki ortaya koyamam��t�r. Koroner
hastal�klar�n �nlenmesine y�nelik statinlerle yap�lan primer ve sekonder
korunma �al��malar� hem y�ksek hem de normale yak�n serum kolesterol d�zeyi
olan hastalarda kolesterol d�zeylerini d���rmenin koroner morbidite ve
mortaliteyi net bir �ekilde azaltt���n� kesin bir �ekilde ortaya koymu�tur. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>&nbsp;</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;punctuation-wrap:simple;text-autospace:none'><span lang=TR
style='font-family:Tahoma;mso-ansi-language:TR'>G�n�m�zde yak�n zamana dek inme
veya G�A'l� hastalarda lipid d�zeylerini d���r�c� m�dahalelerin inme s�kl���
veya inmeye ba�l� mortalite �zerindeki etkilerini do�rudan ortaya koymu� bir
�al��ma yoktu. Statin grubu ila�lar�n kullan�m� ile inme riski aras�ndaki
ili�ki koroner arter hastal�klar�n�n primer veya sekonder korunmas�na y�nelik
�al��malar�ndan elde edilmi� verilere dayanmaktayd�. Statin grubu ila�larla
yap�lan sekonder korumaya y�nelik �al��malar�n meta-analizinde statinlerin inme
riskinde ortalama %20-25 oran�nda azalmaya yol a�t��� g�sterilmi�ti. Heart
Protection Trial �al��mas� y�ksek riskli yakla��k 20 000 ki�ilik bir hasta
grubunda statin tedavisinin etkisini ara�t�rm�� bir �al��mad�r. Bu �al��ma
iskemik inmeli hastalarda cinsiyet, ya� ve total veya LDL kolesterol
de�erlerinden ba��ms�z olarak tekrarlay�c� �l�mc�l veya �l�mc�l olmayan iskemik
inme s�kl��� ile inme d��� maj�r bir vask�ler olay geli�me riskinin yakla��k
%25 d�zeyinde azald���n� g�steren ilk �al��mad�r. Bu �al��ma inme riskine
y�nelik yap�lm�� metaanaliz �al��malar�n� desteklemektedir. </span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt;line-height:
150%;layout-grid-mode:char;punctuation-wrap:simple;text-autospace:none'><span
lang=TR style='font-family:Tahoma;mso-ansi-language:TR'>Statin tedavisinin
yanl�zca iskemik inmeli hasta toplulu�undaki etkisini ara�t�ran SPARCLE
�al��mas�nda da sekonder inme ve kardiyovask�ler olaylar�n s�kl���nda azalma
saptanm��t�r.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:150%'><b><span lang=TR style='font-size:
10.0pt;line-height:150%;font-family:Tahoma;mso-ansi-language:TR'>KAYNAKLAR</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Genel</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Barnett
HJM, Mohr JP, Stein BM, Yatsu FM. Stroke: Pathophysiology, Diagnosis, and
Management. 3. Bask�, New York, Churchill Livingstone, 1998.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Warlow
CP, Dennis MS, van Gijn J, Hankey GJ, Sandercock PAG, Bamford JM, Wardlaw JM.
Stroke: Practical Guide to Management. 2. Bask�, Oxford, Blackwell Science Ltd,
2001</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Adams
HP, del Zoppo GJ, von Kummer R. Management of Stroke: A Practical Guide for the
Prevention, Evaluation, and Treatment of Acute Stroke. 2. Bask�, West Islip,
Professional Communications, 2002.</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Kennedy
RL. Management of acute stroke. The Lancet Neurology 2002; 1: 41-50</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�nme �nitesi</span></b><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
EN-GB'>�</span><span lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:EN-GB'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Stroke
Unit Trialists' Collaboration: Collaborative systematic review of the randomised
trials of organised inpatient (stroke unit) care after stroke. BMJ 1997;
314:1151-1159.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Stroke
Unit Trialists' Collaboration: Organised inpatient (stroke unit) care for
stroke. Stroke Unit Trialists' Collaboration. In Cochrane Database Syst Rev.
2001.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut �nme ve
Hipertansiyon</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Blood
pressure in Acute Stroke Collaboration (BASC). Stroke Module of the Cochrane
Database of Systematic Reviews,[updated 03 June 1997]. The Cochrane Library
[database on disc and CDROM]. The Cochrane Collaboration. 3rd ed. Oxford:
Update Software, 1997.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�skemik �nme
ve Tromboliz</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>The
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study
Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med
1995; 333:1581-1587.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt'><span
lang=TR style='font-size:10.0pt;line-height:115%;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;line-height:115%;font-family:
"Times New Roman";mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;line-height:115%;font-family:Tahoma;
mso-ansi-language:TR'><a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Hacke%20W%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Hacke W</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Kaste%20M%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Kaste M</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Bluhmki%20E%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Bluhmki E</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Brozman%20M%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Brozman M</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22D%C3%A1valos%20A%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>D�valos A</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Guidetti%20D%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Guidetti D</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Larrue%20V%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Larrue V</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Lees%20KR%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Lees KR</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Medeghri%20Z%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Medeghri Z</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Machnig%20T%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Machnig T</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Schneider%20D%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Schneider D</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22von%20Kummer%20R%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>von Kummer R</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Wahlgren%20N%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Wahlgren N</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Toni%20D%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Toni D</span></a>;
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22ECASS%20Investigators%22%5BCorporate%20Author%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>ECASS
Investigators</span></a>. Thrombolysis with alteplase 3 to 4.5 hours after
acute ischemic stroke. <a
href="javascript:AL_get(this,%20'jour',%20'N%20Engl%20J%20Med.');"><span
style='color:windowtext;text-decoration:none;text-underline:none'>N Engl J Med</span></a>
&nbsp;<span class=ti2><span style='font-family:Tahoma'>2008; 359: 1317-1329.</span></span></span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal;
text-autospace:none'><span lang=TR style='font-size:10.0pt;font-family:Symbol;
mso-ansi-language:TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:
"Times New Roman";mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M,
Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase
for acute ischemic stroke. The PROACT II study: a randomized controlled trial.
Prolyse in acute cerebral thromboembolism. <i>JAMA</i>. 1999;282:2003�2011</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:18.0pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>&nbsp;</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal;
text-autospace:none'><span lang=TR style='font-size:10.0pt;font-family:Symbol;
mso-ansi-language:TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:
"Times New Roman";mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>Flint AC, Duckwiler GR, Budzik RF, Liebeskind DS, Smith WS. MERCIand Multi
MERCI Writing Committee. Mechanical thrombectomy ofintracranial internal
carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials.
Stroke. 2007;38:1274 �1280.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut �skemik
�nmede Cerrahi Tedaviler</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Gurol
ME, St. Louis EK. Treatment of Cerebellar Masses. Current Treatment Options in
Neurology 2008; 10:138�150.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal;text-autospace:none'><span lang=TR style='font-size:10.0pt;font-family:
Symbol;mso-ansi-language:TR'>�</span><span lang=TR style='font-size:7.0pt;
font-family:"Times New Roman";mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><span lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:
TR'>K Vahedi, J Hofmeijer and E Juettler, Vicaut E, George B, Algra A, Amelink
GJ, Schmiedeck P, Schwab S, Rothwell PM, Bousser MG, van der Worp HB, Hacke W;
and for the DECIMAL, DESTINY, and HAMLET investigators. Early decompressive
surgery in malignant infarction of the middle cerebral artery: a pooled
analysis of three randomised controlled trials. Lancet Neurol. 2007;6:215�222.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Akut �skemik
�nme ve Aspirin</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>CAST
(Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised
placebo-controlled trial of early aspirin use in 20 000 patients with acute
ischaemic stroke. Lancet 1997; 349:1641-1649.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
EN-GB'>�</span><span lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:EN-GB'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>International
Stroke Trial Collaborative Group. The International Stroke Trial (IST): A
randomized trial of aspirin, subcutaneous heparine , both or neither&nbsp;
among 19435 patients with acute ischemic stroke. Lancet 1997; 349:1559-81</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�skemik �nme
ve Antiplatelet Tedavi</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Antiplatelet
Trialists� Collaboration. Collaborative overview of randomised trials of
antiplatelet therapy I. Prevention of death, myocardial infarction, and stroke
by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;
308:81-106. </span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Antithrombotic
Trialists'&nbsp;Collaboration. Collaborative meta-analysis of randomised trials
of antiplatelet therapy for prevention of death, myocardial infarction, and
stroke in high risk patients. BMJ 2002;324:71-86 </span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�skemik
inme ve antikoag�lan tedavi</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Hart
GB, Sherman DG, Easton D et al. Prevention of stroke in patients with
nonvalvular atrial fibrillation. Neurology 1998;51:674-681.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
EN-GB'>�</span><span lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:EN-GB'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:EN-GB'>Report
of the Quality Standards Subcommittee of American Academy of Neurology. Stroke
prevention in patients with nonvalvular atrial fibrillation. Neurology 1998;
51:671-673.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:EN-GB'>�skemik
�nme ve Karotis Endarterektomisi</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Barnett
HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG et al. Benefit of carotid
endarterectomy in patients with symptomatic moderate or severe stenosis: North
American Symptomatic Carotid Endarterectomy Trial Collaboration. N Engl J Med
1998;339:1415-1425.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>European
Carotid Surgery Trialists� Collaborative Group. Randomised trial of
endarterectomy for recently symptomatic carotid stenosis: final results of the
MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351:1379-1387.</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
EN-GB'>�</span><span lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:EN-GB'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'><a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Rothwell%20PM%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Rothwell PM</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Eliasziw%20M%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Eliasziw M</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Gutnikov%20SA%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Gutnikov SA</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Warlow%20CP%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Warlow CP</span></a>,
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Barnett%20HJ%22%5BAuthor%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Barnett HJ</span></a>;
<a
href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=Search&amp;Term=%22Carotid%20Endarterectomy%20Trialists%20Collaboration%22%5BCorporate%20Author%5D&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><span
style='color:windowtext;text-decoration:none;text-underline:none'>Carotid
Endarterectomy Trialists Collaboration</span></a> Endarterectomy for
symptomatic carotid stenosis in relation to clinical subgroups and timing of
surgery. <span class=ti2><span style='font-family:Tahoma'><a
href="javascript:AL_get(this,%20'jour',%20'Lancet.');"><span style='color:windowtext;
text-decoration:none;text-underline:none'>Lancet.</span></a> 2004; 363:915-24</span></span></span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Vask�ler Risk
Fakt�rlerine Yakla��m, Genel</span></b><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Sacco
RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick
P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ,
Marks M, Schawamm LH, Tomsick T. Guidelines for prevention of stroke or
transient ischemic attack. Stroke<i>. </i>2006; 37: 577�617</span><span
lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>�nme ve
Hipertansiyon Tedavisi</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>The
Heart Outcomes Prevention Evaluation Study Investigators. Effects of an
angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in
high risk patients. New Eng J of Med 2000; 342:145-153.</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
EN-GB'>�</span><span lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:EN-GB'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Butcher
J. Antihypertensive drug helps prevent stroke recurrence. </span><span
lang=EN-GB style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:EN-GB'>Lancet
2001; 357:2030.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
EN-GB'>�</span><span lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:EN-GB'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:EN-GB'>PROGRESS
Collaborative Group. Randomized trial of perindopril-based blood pressure
lowering regimen among 6105 individuals with previous stroke or transient
ischaemic attack. Lancet 2001; 358: 1033-1041</span><span lang=TR
style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:EN-GB'>�skemik
�nme ve Hiperlipidemi</span></b><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
EN-GB'>�</span><span lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:EN-GB'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:EN-GB'>Cholesterol,
diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45
prospective cohorts. Prospective studies collaboration. Lancet 1995;
346:1647-1653.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>Di
Mascio R, Marchioli R, Tognoni G. Cholesterol reduction and stroke occurrence:
an overview of randomised clinical trials. Cerebrovascular Diseases 2000; 10:
85-92.</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:36.0pt;text-indent:-18.0pt;line-height:
normal'><span lang=TR style='font-size:10.0pt;font-family:Symbol;mso-ansi-language:
TR'>�</span><span lang=TR style='font-size:7.0pt;font-family:"Times New Roman";
mso-ansi-language:TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=TR style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>MRC/BHF
Heart Protection Study of of cholesterol lowering with simvastatin in 20,536
high-risk individuals: a randomised placebo-controlled trial. Lancet
2002;360:7-22</span><span lang=TR style='mso-ansi-language:TR'><o:p></o:p></span></p>

<p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;
margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;line-height:normal'><span
lang=TR style='font-size:12.0pt;font-family:Symbol;mso-ansi-language:TR'>�</span><span
lang=TR style='font-size:7.0pt;font-family:"Times New Roman";mso-ansi-language:
TR'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span lang=TR
style='font-size:10.0pt;font-family:Tahoma;mso-ansi-language:TR'>The Stroke
Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)
Investigators. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack.
N Engl J Med 2006;355:549-559</span><span lang=TR style='mso-ansi-language:
TR'><o:p></o:p></span></p>

</div>

</body>

</html>
